It was a great pleasure to see GenomeWeb features Omixon Target again in a new article in which they describe Vendors are Cautiously Optimistic as Illumina Readies BaseSpace App Store.

Omixon, for instance, is developing an HLA genotyping application for identifying disease associations using whole-genome or whole-exome data as well as from targeted sequencing data, Attila Bérces, the company’s CEO, says. The app, which is currently in beta testing, will also be included in Omixon Target, the company’s desktop software tool for analyzing targeted next-generation sequence data, he adds.

BusinessWire published an article about Almac and Omixon. Almac is launching a Next Generation Sequencing service to support the development of personalized medicine and collaborates with Omixon.

Almac already perform Next Generation Sequencing for Omixon, a bioinformatics company focused on the development of validated data analysis solutions to scientists working in genomics with special emphasis on clinical and diagnostic applications. Attila Bérces, founder and Chief Executive Officer of Omixon said:

“Omixon aims to provide the most accurate and highest quality DNA analysis software. Almac complements our effort by providing the highest quality sequencing data. The MiSeq data we received from Almac is of highest quality which helped Omixon in developing and validating our HLA-typing software. Next Generation Sequencing can revolutionize HLA-typing which is carried out on millions of samples annually.”